Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 07/28 05:35:19 pm
44.5 GBp   +1.14%
07/19 VERNALIS : Reaches Milestone In French Oncology Collaboration
07/19 VERNALIS : Achieves a Milestone in Its Oncology Collaboration With S..
07/18 JUNO THERAPEUTI : Vernalis Notes the Acquisition of RedoxTherapies b..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/22/2016 07/25/2016 07/26/2016 07/27/2016 07/28/2016 Date
46.25(c) 45.25(c) 44.5(c) 44(c) 44.5 Last
1 185 941 75 231 263 417 210 065 6 561 Volume
-0.54% -2.16% -1.66% -1.12% +1.14% Change
More quotes
Financials ( GBP)
Sales 2016 11,6 M
EBIT 2016 -30,0 M
Net income 2016 -24,3 M
Finance 2016 46,0 M
Yield 2016 -
Sales 2017 19,7 M
EBIT 2017 -25,0 M
Net income 2017 -22,7 M
Finance 2017 23,9 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 16,0x
EV / Sales2017 10,5x
Capitalization 232 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
07/19 VERNALIS : Reaches Milestone In French Oncology Collaboration
07/19 VERNALIS : Achieves a Milestone in Its Oncology Collaboration With Servier
07/18 JUNO THERAPEUTICS : Vernalis Notes the Acquisition of RedoxTherapies by Juno The..
07/15 VERNALIS : Notes Juno Therapeutics To Buy Partner RedoxTherapies
07/15 VERNALIS : Notes the Acquisition of RedoxTherapies by Juno Therapeutics
07/11 VERNALIS : Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Compa..
07/08 VERNALIS : Year-end Trading Update and Notice of Results
07/08 VERNALIS : Completes Study On CCP-08 Cough And Cold Product
07/08 VERNALIS : Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Compa..
07/07 VERNALIS : Year-End Trading Update and Notice of Results
More news
Sector news : Biotechnology & Medical Research - NEC
03:28pDJU.S. HOT STOCKS : Hot Stocks to Watch
02:56pDJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/17 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 0,84  GBP
Spread / Average Target 90%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
Carol C. Ferguson Senior Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-37.92%305
INCYTE CORPORATION-18.19%16 646
CELLTRION, INC.--.--%10 582
LONZA GROUP AG11.40%9 818
QUINTILES TRANSNATIONA..9.23%8 975
ALKERMES PLC-35.74%7 827
More Results